Filing Details
- Accession Number:
- 0001209191-20-053312
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-02 17:54:47
- Reporting Period:
- 2020-10-01
- Accepted Time:
- 2020-10-02 17:54:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1124140 | Exact Sciences Corp | EXAS | Services-Commercial Physical & Biological Research (8731) | 204782291 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1306119 | T Kevin Conroy | C/O Exact Sciences Corp. 5505 Endeavor Lane Madison WI 53719 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-10-01 | 11,698 | $102.86 | 936,641 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-10-01 | 9,391 | $103.57 | 927,250 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-10-01 | 5,200 | $104.70 | 922,050 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-10-01 | 1,136 | $105.20 | 920,914 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 26,305 | Indirect | Held in 401(k) Plan |
Common Stock | 21,730 | Indirect | Held in Grantor Retained Annuity Trust |
Common Stock | 21,730 | Indirect | Held in Grantor Retained Annuity Trust |
Common Stock | 21,729 | Indirect | Held in Grantor Retained Annuity Trust |
Footnotes
- The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which trading plan was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.16 to $103.15, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.16 to $104.15, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.16 to $105.14, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.16 to $105.31, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
- In addition to the shares of Common Stock reported on this Form 4, which total 1,012,408 shares, Mr. Conroy also holds, in the aggregate, an additional 1,279,310 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.